bpc 157 vs bpc 157 acetate FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them bpc 157 vs bpc 157

But controlled human efficacy data is sparse, and the single Phase 2 trial tested oral administration rather than the subcutaneous injection most users employ today

This stability is unusual among peptide research compounds and allows investigators to use BPC-157 in both oral and parenteral administration designs in pre-clinical models

Any use should be physician-guided

while neither compound is known to impair lactation, the concentrated doses delivered by weekly injections may alter milk taste or infant gastrointestinal tolerance

The right choice depends on your dosing protocol and the type of syringe you are using